<i>The effect of the 5‐HT₃ receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients</i>

Abstract

In non-constipated irritable bowel syndrome patients, 3 weeks of treatment with a 5-hydroxytryptamine-3 receptor antagonist decreases brain activity in response to unanticipated, anticipated and delivered aversive rectal stimuli in structures of the emotional motor system, and this is associated with a decrease in gastrointestinal symptoms.